Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance

Cell Cycle

Volumn 11, Issue 8, 2012, Pages 1656-1663

  Ogawa, Takenori ^a,c   Liggett, Thomas E ^b   Melnikov, Anatoliy A ^b   Monitto, Constance L ^a   Kusuke, Daniela ^a   Shiga, Kiyoto ^c   Kobayashi, Toshimitsu ^c   Horii, Akira ^c   Chatterjee, Aditi ^a   Levenson, Victor V ^b   Koch, Wayne M ^a   Sidransky, David ^a   Chang, Xiaofei ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cetuximab; DAPK; Erlotinib; Methylation; NSCLC

Indexed keywords

CETUXIMAB; ERLOTINIB; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CARCINOMA CELL; CONTROLLED STUDY; DEATH ASSOCIATED PROTEIN KINASE GENE; DNA METHYLATION; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SENSITIZATION; GENE; GENE SILENCING; GENETIC TRANSFECTION; HEAD AND NECK CARCINOMA; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; PROMOTER REGION; PROTEIN METHYLATION; SQUAMOUS CELL CARCINOMA;

EID: 84860319366     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20120     Document Type: Article

References (36)

1. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78; PMID:16467544; http://dx.doi.org/10.1056/ NEJMoa053422.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32; PMID:16014882; http://dx.doi.org/10.1056/NEJMoa050753.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6; PMID:17452677; http://dx.doi.org/10. 1200/JCO.2006.07.9525.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39; PMID:15118073; http://dx.doi.org/10.1056/NEJMoa040938.
5. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-44; PMID:16014883; http://dx.doi.org/10.1056/NEJMoa050736.
6. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5; PMID:16618717; http://dx.doi.org/10.1158/0008-5472.CAN-06-0191.
7. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-9; PMID:18202412; http://dx.doi.org/10.1200/JCO.2007.12.5906.
8. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10:687-92; PMID:11257100; http://dx.doi.org/10. 1093/hmg/10.7.687.
9. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-4; PMID:11070098; http://dx.doi.org/10.1056/NEJM200011093431901.
10. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568-74; PMID:12692539; http://dx.doi.org/10. 1038/nm852.
11. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 2010; 70:2870-9; PMID:20215521; http://dx.doi.org/10. 1158/0008-5472.CAN-09-3427.
12. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10:4420-6; PMID:15240532; http://dx.doi.org/10.1158/1078-0432.CCR-03-0732.
13. Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Chavez-Blanco A, Revilla-Vazquez A, Benitez-Bribiesca L, et al. Global DNA hypermethylation- associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J Transl Med 2006; 4:32; PMID:16893460; http://dx.doi.org/10.1186/1479-5876-4-32.
14. Levenson VV. DNA methylation as a universal biomarker. Expert Rev Mol Diagn 2010; 10:481-8; PMID:20465502; http://dx.doi.org/10.1586/erm.10.17.
15. Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med 2010; 10:123-32; PMID:20196733; http://dx.doi.org/10.2174/156652410790963303.
16. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 2008; 14:97-107; PMID:18172258; http://dx.doi.org/10.1158/1078-0432.CCR-07- 0722.
17. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006; 98:996-1004; PMID:16849682; http://dx.doi.org/10.1093/jnci/djj265.
18. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res 2010; 16:3463-72; PMID:20592015; http://dx.doi.org/10.1158/1078-0432.CCR-09-3304.
19. Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, et al. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci 2010; 290:16-21; PMID:20064646; http://dx.doi.org/10. 1016/j.jns.2009.12.018.
20. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 1995; 9:15-30; PMID:7828849; http://dx.doi.org/10.1101/gad.9.1.15.
21. Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH. TGFbeta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 2002; 4:51-8; PMID:11740493; http://dx.doi.org/10.1038/ncb731.
22. Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, Spivak-Kroizaman T, et al. DAP-kinase participates in TNFalpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 1999; 146:141-8; PMID:10402466.
23. Gozuacik D, Kimchi A. DAPk protein family and cancer. Autophagy 2006; 2:74-9; PMID:17139808.
24. van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003; 17:211-9; PMID:12529680; http://dx.doi.org/10.1038/sj.leu.2402768.
25. De Cesare M, Perego P, Righetti SC, Pratesi G, Carenini N, Rivoltini L, et al. Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. Eur J Cancer 2005; 41:1213-22; PMID:15911246; http://dx.doi.org/10.1016/j.ejca.2005.03.001.
26. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Müller M, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4:232-4; PMID:9461199; http://dx.doi.org/10.1038/ nm0298-232.
27. Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001; 91:846-50; PMID:11275990; http://dx.doi.org/10.1002/ 1097-0215(200002)9999:9999〈::AIDIJC1131〉3.0.CO;2-Y.
28. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000; 92:34-41; PMID:10620631; http://dx.doi.org/10.1093/jnci/92.1.34.
29. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7:2984-97; PMID:11595686.
30. Chen CH, Wang WJ, Kuo JC, Tsai HC, Lin JR, Chang ZF, et al. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J 2005; 24:294-304; PMID:15616583; http://dx.doi.org/10.1038/sj. emboj.7600510.
31. Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T, Hirakawa K. Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res 2010; 30:915-21; PMID:20393015.
32. Holleman A, den Boer ML, de Menezes RX, Cheok MH, Cheng C, Kazemier KM, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance and outcome in childhood acute lymphoblastic leukemia. Blood 2006; 107:769-76; PMID:16189266; http://dx.doi.org/10.1182/ blood-2005-07-2930.
33. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009; 15:1585-92; PMID:19190133; http://dx.doi.org/10.1158/1078-0432. CCR-08-2068.
34. Melnikov AA, Scholtens DM, Wiley EL, Khan SA, Levenson VV. Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn 2008; 10:93-101; PMID:18165279; http://dx.doi.org/10.2353/jmoldx.2008.070077.
35. Melnikov AA, Gartenhaus RB, Levenson AS, Motchoulskaia NA, Levenson Chernokhvostov VV. MSRE-PCR for analysis of gene-specific DNA methylation. Nucleic Acids Res 2005; 33:93; PMID:15944447; http://dx.doi.org/10.1093/nar/ gni092.
36. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6; PMID:8790415; http://dx.doi.org/10.1073/pnas.93.18.9821.